Expert review of pharmacoeconomics & outcomes research
-
Expert Rev Pharmacoecon Outcomes Res · Feb 2015
Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.
Pharmaceutical expenditure is rising by 16% per annum in China and is now 46% of total expenditure. Initiatives to moderate growth include drug pricing regulations and encouraging international non-proprietary name prescribing. However, there is no monitoring of physician prescribing quality and perverse incentives. ⋯ Considerable opportunities to improve prescribing efficiency in China.